Alphamab

News

Pathos AI signs two cancer deals with Alphamab and AZ

Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.

News

Glenmark licenses cancer drug from China’s Alphamab, 3D Med

India’s Glenmark Pharma has added to its oncology pipeline by licensing rights to a checkpoint inhibitor from China’s Jiangsu Alphamab Biopharmaceuticals and 3D Medicines

News

J&J scores EU approval for Tecvayli combo in second line

Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks